Titelbild

Advisors

 
Portrait

Prof. Ian Hunneyball

Prof. Hunneyball has over 40 years experience in the pharmaceutical and biotech industry sector covering all aspects of research and development. Ian is Senior Vice president, Programme Management, at Evotec AG and acts as a consultant to Topas Therapeutics to advise on all aspects of the development programmes. He holds a BSc in Medical Biochemistry and a PhD in Experimental Pathology from the University of Birmingham, UK. Ian’s career includes serving as Director of Research & Development for BASF Pharma in the UK. Prior to that he was global Director of Research for Boots Pharmaceuticals.

 
Portrait

Prof. Ian Hunneyball

Prof. Hunneyball has over 40 years experience in the pharmaceutical and biotech industry sector covering all aspects of research and development. Ian is Senior Vice president, Programme Management, at Evotec AG and acts as a consultant to Topas Therapeutics to advise on all aspects of the development programmes. He holds a BSc in Medical Biochemistry and a PhD in Experimental Pathology from the University of Birmingham, UK. Ian’s career includes serving as Director of Research & Development for BASF Pharma in the UK. Prior to that he was global Director of Research for Boots Pharmaceuticals.

 
Portrait

Prof. Dr. med. vet. Chris Rundfeldt

Prof. Rundfeldt has more than 20 years of drug development experience as an independent regulatory toxicologist as well as a drug development and regulatory affairs executive in several biopharmaceutical companies. He previously worked as a drug development/regulatory affairs consultant at Brinker Pharma Consulting and was also Vice President Science and Pre-clinical at Forward Pharma GmbH. He previously served as Head of Clinical Research and Vice President of Pharmacology at elbion AG, a company he co-founded, and was Head of Pharmacology at Arzneimittelwerk Dresden, part of ASTA medica AG.

Prof. Rundfeldt is a board-certified pharmacologist and toxicologist and received his PhD and DVM from the Tierärztliche Hochschule Hannover, Germany.

 
Portrait

Prof. Dr. med. vet. Chris Rundfeldt

Prof. Rundfeldt has more than 20 years of drug development experience as an independent regulatory toxicologist as well as a drug development and regulatory affairs executive in several biopharmaceutical companies. He previously worked as a drug development/regulatory affairs consultant at Brinker Pharma Consulting and was also Vice President Science and Pre-clinical at Forward Pharma GmbH. He previously served as Head of Clinical Research and Vice President of Pharmacology at elbion AG, a company he co-founded, and was Head of Pharmacology at Arzneimittelwerk Dresden, part of ASTA medica AG.

Prof. Rundfeldt is a board-certified pharmacologist and toxicologist and received his PhD and DVM from the Tierärztliche Hochschule Hannover, Germany.

 
Portrait

Dr. med. vet. Susanne Wagner

Dr. Wagner has more than 25 years in nanodrug research and development. Starting at the Dept. of Contrast Media Research at Schering AG in cooperation with the Institute für Diagnostikforschung GmbH Berlin she participated in the development of Resovist® and liposomal encapsulated iodinated contrast media with responsibilites in the area of in-vivo imaging and safety pharmacology. Later on as a Co-Founder of Ferropharm GmbH she successfully managed the whole line of development up to clinical trials phase II of an iron oxide based contrast medium. With this background she has a unique expertise in preclinical and clinical development of iron oxide based nanodrugs including aspects of physics, chemistry and non-clinical testing with special focus on regulatory requirements.

 
Portrait

Dr. med. vet. Susanne Wagner

Dr. Wagner has more than 25 years in nanodrug research and development. Starting at the Dept. of Contrast Media Research at Schering AG in cooperation with the Institute für Diagnostikforschung GmbH Berlin she participated in the development of Resovist® and liposomal encapsulated iodinated contrast media with responsibilites in the area of in-vivo imaging and safety pharmacology. Later on as a Co-Founder of Ferropharm GmbH she successfully managed the whole line of development up to clinical trials phase II of an iron oxide based contrast medium. With this background she has a unique expertise in preclinical and clinical development of iron oxide based nanodrugs including aspects of physics, chemistry and non-clinical testing with special focus on regulatory requirements.